In a report issued on July 6, Joseph Schwartz from SVB Securities maintained a Buy rating on Applied Molecular Transport (AMTI – Research Report). The company’s shares closed last Thursday at $2.27, close to its 52-week low of $1.97.
According to TipRanks.com, Schwartz is ranked 0 out of 5 stars with an average return of -10.6% and a 35.6% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Ultragenyx Pharmaceutical, and Mereo Biopharma Group Plc.
Applied Molecular Transport has an analyst consensus of Strong Buy, with a price target consensus of $9.53, which is a 326.4% upside from current levels. In a report issued on July 6, JMP Securities also reiterated a Buy rating on the stock with a $21.00 price target.
The company has a one-year high of $46.49 and a one-year low of $1.97. Currently, Applied Molecular Transport has an average volume of 424.6K.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AMTI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Applied Molecular Transport Inc is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Its proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of therapeutic payloads across the intestinal epithelium (IE) barrier. Its product candidate, AMT-101, is an oral IL-10 fusion protein that has been designed for active transport across the IE barrier into local GI tissue. IL-10 is a potent immunomodulatory cytokine that is known to be the master regulator of immune homeostasis, including within GI mucosal tissue.
Read More on AMTI:
- BeiGene (BGNE) Receives a Hold from SVB Securities
- SVB Securities Sticks to Their Buy Rating for Lantheus (LNTH)
- Robert W. Baird Sticks to Its Buy Rating for IVERIC bio (ISEE)
- Robert W. Baird Maintains Their Buy Rating on Sarepta Therapeutics (SRPT)
- Ovintiv (OVV) Receives a Buy from Mizuho Securities